NY-DAVIS-POLK
Davis Polk today announced that the firm is launching a European antitrust practice in Brussels. The practice will be led by Jürgen Schindler and Frances Dethmers.
“The European Commission is a critical antitrust authority. We are excited to be able to offer our clients sophisticated antitrust capabilities with respect to matters under EU law,” said Neil Barr, Davis Polk’s Managing Partner. “We are thrilled to welcome Jürgen and Frances to Davis Polk.”
The firm’s office in Brussels will open in 2023.
Mr. Schindler and Ms. Dethmers join the firm from Allen & Overy, where both served as partners and Mr. Schindler as co-head of the global competition and antitrust group. Mr. Schindler has extensive experience advising clients on complex international, EU and German merger control, cartel and abuse of dominance cases. His practice encompasses a broad range of sectors, including energy, finance, technology, transport (shipping and airlines), raw materials, chemicals, pharmaceuticals, and consumer and industrial products. In addition, Mr. Schindler litigates before the European courts in Luxembourg.
Mr. Schindler’s practice has extensive geographic coverage; he has advised clients in Europe, the United States, Latin America, Asia and the Middle East. He is admitted to practice in Germany, Belgium and New York. He will join Davis Polk as a partner.
He is a Non-Governmental Adviser to the European Commission and to the German Competition Authority at the International Competition Network (ICN), which includes around 140 competition authorities worldwide, and he regularly contributes to the ICN’s cartel and merger working groups. In addition, he is a long-time editorial board member of the ABA’s Antitrust Magazine Online.
Ms. Dethmers’ practice focuses on international, EU and Dutch competition law. She is an economist and a qualified lawyer. She has extensive experience advising clients from a wide range of industries (in particular, pharmaceuticals, health and life sciences, consumer and industrial products, chemicals and packaging) on highly complex merger control procedures, as well as on cartel investigations, abuse of dominance investigations, intellectual property issues and licensing and distribution agreements. Prior to working in private practice, she worked at the Dutch Competition Authority and the European Commission. Her background as an economist gives her unique insight into the economic concepts and analytical tools at the heart of competition law. She is admitted to practice in the Netherlands. She will join Davis Polk as Special Adviser – EU Antitrust.
“Jürgen and Frances are exceptional lawyers with an outstanding reputation in Brussels, and we are thrilled to have them on board to help us launch our EU antitrust practice,” said Art Burke, head of Davis Polk’s Antitrust & Competition practice. “Their significant experience across merger control matters, cartels and antitrust litigation will benefit our clients greatly and will further solidify our position as a leading global antitrust firm.”
Davis Polk is recognized as a preeminent firm in antitrust and competition law, including with top-tier rankings from publications such as Global Competition Review, Benchmark Litigation and Chambers USA. Clients rely on Davis Polk’s deep experience across the full spectrum of antitrust and competition matters. The firm steers clients through sensitive antitrust investigations and high-stakes litigation, including class actions and government enforcement actions. Davis Polk also serves in a lead role for large defense groups, including in cases alleging cartel behavior in numerous industries and financial markets. Having addressed and resolved antitrust issues presented by thousands of transactions across all economic sectors, the firm is widely recognized in particular for its work on cross-border combinations and routinely acts as coordinating counsel for international merger control review for complex transactions.
Mr. Schindler said, “Frances and I are very excited to be joining Davis Polk, a firm we have long held in high esteem. We have been struck by the strong culture that permeates throughout the firm, and we very much look forward to working with this fantastic team and helping the firm to execute on this strategic expansion of its global antitrust capabilities. We are very grateful for our time as partners at Allen & Overy.”
Ranked as a leading EU competition lawyer by Chambers Europe, Mr. Schindler in 1999 graduated from the University of Hamburg and earned an LLM in European Law from the College of Europe in Bruges. In 2007, he earned an LLM from Georgetown University Law Center focusing on U.S. antitrust law and economics. Ms. Dethmers earned a master’s degree in economics in 1998 and a master’s degree in law in 2001, both from the University of Amsterdam.
About Davis Polk.
Davis Polk & Wardwell LLP (including its associated entities) is an elite global law firm with world-class practices across the board. Clients know they can rely on us for their most challenging legal and business matters. From offices in the world’s key financial centers and political capitals, our more than 1,000 lawyers collaborate seamlessly to deliver exceptional service, sophisticated advice and creative, practical solutions. Visit davispolk.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005803/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference15.1.2026 01:40:00 CET | Press release
Samsung Bioepis plans to secure 20 biosimilars in its products and pipeline by 2030The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab, and ocrelizumab, in addition to pembrolizumab currently in Phase 1 and 3 clinical studiesHaving secured investigational new drug application (IND) clearance from the U.S. Food and Drug Administration (FDA), SBE303, Samsung Bioepis’ novel antibody-drug conjugate (ADC) engineered to target Nectin-4, will enter into the Phase 1 first-in-human clinical trial this yearSamsung Bioepis plans to add one novel therapeutic candidate in clinical study every year Samsung Epis Holdings (KRX: 0126Z0) today shared corporate progress and updates at the 44th J.P. Morgan Healthcare Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114206458/en/ Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings "2026 is a mon
Most Delivered Light-Entry Jet Cessna Citation M2 Gen2 With Garmin Autothrottles Enters Into Service, Bringing Greater Control and Precision to Pilots14.1.2026 20:30:00 CET | Press release
The Cessna Citation M2 Gen2 with Garmin Autothrottles recently entered into service. Certified by the Federal Aviation Administration in October 2025, the integration of Garmin’s Autothrottle system in the Citation M2 Gen2 further supports the most delivered light-entry jet’s capabilities by bringing greater control and precision to pilots. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114646844/en/ Most delivered light-entry jet Cessna Citation M2 Gen2 with Garmin Autothrottles enters into service, bringing greater control and precision to pilots (Photo Credit: Textron Aviation). The Cessna Citation M2 Gen2 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “We continue to invest in our products to provide customers with the best aviation experience in the world," said Lannie O’Bannion, senior vice president, Sales & Marketing. “The M2 Gen2 leads its segment as the most delivered
TwentyTwo Real Estate and Farallon Capital Complete €761 Million Investment in Isemia, a €1.2bn Healthcare Real Estate Company Created With emeis14.1.2026 18:30:00 CET | Press release
TwentyTwo Real Estate, an independent European real estate investment and management firm, announces the completion, alongside Farallon Capital, of a €761 million investment that led to the creation of Isemia (www.isemiabyemeis.com), a leading healthcare real estate company holding a €1.2 billion portfolio of assets operated by emeis. The transaction represents a significant milestone in TwentyTwo Real Estate’s long-term investment strategy focused on healthcare and operational living real estate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114262830/en/ Fachklinik Schömberg Isemia comprises 68 high-quality assets across France, Germany and Spain, with a balanced mix of nursing homes (48%) and clinics (52%). The portfolio benefits from strong fundamentals and resilient operating performance. All properties will continue to be operated by emeis under long-term lease agreements, ensuring continuity of care for residents
AI’s Water Demand to Surge Nearly 130% by 2050 – New Research Shows How to Build a Water-Secure AI Economy14.1.2026 16:00:00 CET | Press release
Analysis finds AI could add 30 trillion liters of annual water demand, but targeted reuse and digital infrastructure investments can substantially offset demand and protect communities The rapid global expansion of artificial intelligence is set to drive a 129% increase in water demand across the AI value chain by 2050, according to new research by Xylem (NYSE: XYL) and Global Water Intelligence (GWI). Watering the New Economy: Managing the Impacts of the AI Revolution provides the most comprehensive assessment to date of how AI is reshaping global water use. It also highlights practical ways to meet that demand while strengthening water security for communities. Spending on AI is forecast to approach $2 trillion in 2026,1 accelerating infrastructure build-out worldwide. By the middle of the century, this expansion is projected to add 30 trillion liters of water demand, annually, fueled by a surge in power generation (~54% of the increase), semiconductor fabrication (~42%), and data ce
ACCELQ Crowned Leader and Customer Favorite in The Forrester Wave™ for Autonomous Testing Platforms14.1.2026 16:00:00 CET | Press release
Agentic Test Automation Pioneer Caps Record-Breaking Year of Growth and "AI-Based Engineering Solution of the Year" Honors Forrester has named ACCELQ a Leader in The Forrester Wave™: Autonomous Testing Platforms, Q4 2025. This marks the third consecutive Wave in which ACCELQ has been recognized as a Leader. Notably, this evaluation placed strong emphasis on generative AI innovation and real-world customer adoption. ACCELQ received the highest scores for both capabilities and vision and was the only platform to be recognized as a Customer Favorite, earning a "double halo" for exceptional customer endorsement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113112861/en/ ACCELQ recognized as a Leader and Customer Favorite in The Forrester Wave™️: Autonomous Testing Platforms, Q4 2025, validating its agentic, GenAI-embedded testing vision. According to the Forrester report, ACCELQ received the highest score among all evaluate
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
